In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Allena Pharmaceuticals (ALNA). The company’s shares closed last Monday at $1.64, close to its 52-week low of $1.55.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 18.2% and a 45.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allena Pharmaceuticals with a $14.67 average price target, implying a 757.9% upside from current levels. In a report issued on November 8, B.Riley FBR also reiterated a Buy rating on the stock with a $11.00 price target.
See today’s analyst top recommended stocks >>
Based on Allena Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.27 million. In comparison, last year the company had a GAAP net loss of $9.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.
